Previous 10 | Next 10 |
Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021 Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe Rheumatoid Arthritis in Second Half of 2021 Advancing ATI-450 int...
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this event. For further details see: Aclaris Therapeutics (ACRS) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow
Aclaris Therapeutics ([[ACRS]] -4.7%) has completed the enrollment of a Phase 2a trial of ATI-1777, an investigational topical “soft” Janus kinase ("JAK") 1/3 inhibitor, in the treatment of moderate to severe atopic dermatitis (“AD”).The multicenter, rand...
Enrollment Completed Data Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, tod...
BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating. ATI-450 is a novel oral MK2 inhibitor that demonstrated comparable efficacy and superior safety over Jak inhibitors during Ph2. The oral route of administration offers a superior convenience over biological...
Aclaris Therapeutics (ACRS): Q4 GAAP EPS of -$0.30 misses by $0.04.Revenue of $1.58M (+43.6% Y/Y) beats by $0.19M.Shares -3.2% PM.Press Release For further details see: Aclaris Therapeutics EPS misses by $0.04, beats on revenue
Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid...
Aclaris Therapeutics (ACRS) jumped 13% after a report that the company hired banks to explore a potential sale.The company allegedly has hired two investments banks to consider a potential sale, according a Street Insider report.Aclaris didn't immediately return Seeking Alpha reques...
WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present ...
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at th...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...